Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV)
Publication
, Journal Article
Suhy, D; Patel, K; Kilfoil, G; Wyles, DL; Naggie, S; Lawitz, E; Bradley, S; Lindell, P
Published in: HEPATOLOGY
December 1, 2015
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
December 1, 2015
Volume
62
Issue
6
Start / End Page
1386A / 1386A
Publisher
WILEY-BLACKWELL
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Suhy, D., Patel, K., Kilfoil, G., Wyles, D. L., Naggie, S., Lawitz, E., … Lindell, P. (2015). Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV). HEPATOLOGY, 62(6), 1386A-1386A.
Suhy, David, Keyur Patel, Georgina Kilfoil, David L. Wyles, Susanna Naggie, Eric Lawitz, Stephen Bradley, and Per Lindell. “Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV).” HEPATOLOGY 62, no. 6 (December 1, 2015): 1386A-1386A.
Suhy D, Patel K, Kilfoil G, Wyles DL, Naggie S, Lawitz E, et al. Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV). HEPATOLOGY. 2015 Dec 1;62(6):1386A-1386A.
Suhy, David, et al. “Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV).” HEPATOLOGY, vol. 62, no. 6, WILEY-BLACKWELL, Dec. 2015, pp. 1386A-1386A.
Suhy D, Patel K, Kilfoil G, Wyles DL, Naggie S, Lawitz E, Bradley S, Lindell P. Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV). HEPATOLOGY. WILEY-BLACKWELL; 2015 Dec 1;62(6):1386A-1386A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
December 1, 2015
Volume
62
Issue
6
Start / End Page
1386A / 1386A
Publisher
WILEY-BLACKWELL
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics